Significance of the PSA-concentration for the detection of prostate cancer;Bedeutung des PSA-wertes für die diagnostik des prostatakarzinoms

Pathologe

Volumn 26, Issue 6, 2005, Pages 469-472

  Stachon, A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Benign prostatic hyperplasia; Pre analytical procedures; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANALYTIC METHOD; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; PATIENT INFORMATION; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; TISSUE SECTION;

AGED; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 27744563113     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-005-0788-8     Document Type: Article

References (19)

1. Carter HB, Pearson JD, Metter EJ et al. (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220
2. Catalona WJ, Smith DS, Ratliff TL et al. (1991) Measurement of prostate-specific antigen in serum as screening test for prostate cancer. N Engl J Med 324:1156-1161
3. Catalona WJ, Partin AW, Slawin KM et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542-1547
4. Chrisstensson A, Laurell CB, Lilja H (1990) Enzymatic activity of prostate-specific antigen and its reaction with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-763
5. Jain S, Bhojwani AG, Mellon JK (2002) Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivates and novel markers. Postgrad Med J 78:646-650
6. Jung K, Stephan C, Lein M et al. (1996) Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 42:1026-1033
7. Oberpenning F, Schmid HP, Fuchs-Surdel W et al. (2002) The impact of intraoperative manipulation of the prostate on total and free prostate-specific antigen. Int J Biol Mark 17:154-160
8. Oesterling JE, Jacobsen SJ, Chute CG et al. (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270:860-864
9. Okihara K, Cheli CD, Partin AW et al. (2002) Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 167:2017-2023
10. Reiter W, Oberneder R, Schmeller N (2001) Tumor markers in prostate cancer. J Lab Med 25:337-342
11. Schaid DJ (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13:R103-R121
12. Schmid HP, Stamey TA, McNeal JE et al. (1994) Effect of the natural history on management of adenocarcinoma of the prostate. Urologe A 33:144-148
13. Schröder FH, Wildhagen MF (2002) Low levels of PSA predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology 59:462
14. Schröder FH, van der Cruijsen-Koeter I, de Koning HJ et al. (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163:806-812
15. Semjonow A, Oberpenning F, Weining C et al. (2002) Unterschiede zwischen PSA-Bestimmungsverfahren. In: Fornara P, Semjonow A (Hrsg) PSA: Der Weg zum Befund - Präanalytik und Analytik des prostataspezifischen Antigens. Zuckschwerdt, München, S 83-113
16. Stieber P (2001) Sensible use of tumor markers. J Lab Med 25:327-336
17. Strohmaier WL (2002) Gesamt-PSA - patientenabhängige Einflussgrößen. In: Fornara P, Semjonow A (Hrsg) PSA: Der Weg zum Befund - Präanalytik und Analytik des prostataspezifischen Antigens. Zuckschwerdt, München, S 1-15
18. Vashi AR, Wojno KJ, Henricks W et al. (1997) Determination of the "reflex range" and appropriate cut-points for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. U rology 49:19-27
19. Virtanen A, Gomari M, Kranse R, Stenman U-H (1999) Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45:987-994